GlassScriptPhysician profile
Lawrence S Weiss
NPI 1912996422
$9,031.04
in general payments reported to CMS, 2019-2025
32 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $460 · 2021: $2,564 · 2022: $1,142 · 2023: $1,542 · 2024: $1,319 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443 · Education: $91.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.05 |
| Education | $91.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,765.37 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,528.12 | 2020-2021 | |
| Abbvie INC. | $1,339.27 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $784.86 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $602.09 | 2019-2025 | Dupixent |
| Optinose US, INC. | $486.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $295.08 | 2022-2025 | Nucala |
| Supernus Pharmaceuticals, INC. | $282.87 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $272.84 | 2022 | |
| Medtronic, INC. | $272.70 | 2021-2023 | Stealthstation S8 Platform |
| Aerin Medical INC. | $203.82 | 2022-2025 | |
| Amgen INC. | $203.07 | 2019-2025 | |
| Allergan, INC. | $171.75 | 2020-2022 | |
| Axsome Therapeutics, INC. | $135.49 | 2025 | Symbravo |
| Lundbeck LLC | $92.99 | 2021-2025 | Vyepti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $79.35 | 2020 | |
| Eisai INC. | $60.16 | 2020-2021 | |
| Intersect Ent, INC. | $59.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $57.99 | 2023 | |
| Merck Sharp & Dohme LLC | $52.23 | 2021-2023 | Belsomra |
| Alk-Abello, INC | $51.31 | 2019 | |
| Phadia US INC. | $34.81 | 2021-2024 | Immunocap |
| Stryker Corporation | $33.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $31.22 | 2022 | |
| Arrinex, INC. | $24.89 | 2019 | |
| Galderma Laboratories, L.P. | $18.70 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2021 | |
| Acclarent, INC | $16.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.35 | 2021 | |
| Inspire Medical Systems, INC. | $14.79 | 2025 | Inspire |
| Medtronic USA, INC. | $13.20 | 2019 | |
| Integra Lifesciences Corporation | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.